We are pleased to announce that on 23rd December 2025, China Merchants Securities (HK) Co., Limited (“CMS (HK)”, a subsidiary of China Merchants Securities International Company Limited), acting as one of the Overall Coordinators, Joint Global Coordinators and Joint Bookrunners of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“the Company”, stock code: 3378.HK), successfully assisted the Company to commence trading of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEx”). A total of approximately 18.32 million shares are issued and offered under the Global Offering, at an offer price of HK$32.00 per share, raising a total of approximately HK$586 million.
As one of the Overall Coordinators, CMS (HK) selectively arranged nearly 30 online/offline roadshow meetings since the inception of the project, and invited more than 20 long-only funds, multi-strategy funds, healthcare specialist investors, PE funds, strategic investors, and corporate investors to meet with the Company and thus enabled them to have a better understanding of the Company’s brand and business model. After extensive investor outreach and marketing work, CMS (HK) assisted the Company to complete the listing successfully. Overall, the International Placing received 5.78 times subscription and the Hong Kong Public Offering received 3,074.09 times subscription.
About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
The Company is a biotech company, with in-house expertise and experience in structural biology, translational medicine and clinical development. Since 2016, the Company has developed a product pipeline comprising of one Core Product and nine other pipeline candidates, which are (i) three clinical stage drug candidates focused on oncology, including the Company’s Core Product HX009 and Key Products HX301 and HX044; and (ii) seven preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. Prior to the Track Record Period, the Company also developed HX008, which was transferred to a biopharmaceutical company focusing on oncology therapeutics.